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Abstract
Autism spectrum disorders (ASDs) are estimated to occur among about one percent of children in 
the United States. This estimate is in line with estimates from other industrialized countries. 
However, the identified prevalence of ASDs has increased significantly in a short time period 
based on data from multiple studies including the U.S. Centers for Disease Control and 
Prevention’s (CDC) Autism and Developmental Disabilities Monitoring (ADDM) Network. 
Whether increases in ASD prevalence are partly attributable to a true increase in the risk of 
developing ASD or solely to changes in community awareness and identification patterns is not 
known. It is clear that more children are identified with an ASD now than in the past and the 
impact on individuals, families, and communities is significant. However, disentangling the many 
potential reasons for ASD prevalence increases has been challenging. Understanding the relative 
contribution of multiple factors such as variation in study methods, changes in diagnostic and 
community identification, and potential changes in risk factors is an important priority for the 
ADDM Network and for CDC. This article summarizes the discussion from a workshop that was 
co-sponsored by CDC and Autism Speaks as a forum for sharing knowledge and opinions of a 
diverse range of stakeholders about changes in ASD prevalence. Panelists discussed 
recommendations for building on existing infrastructure and developing new initiatives to better 
understand ASD trends. The information, research, and opinions shared during this workshop add 
Corresponding Author Contact Infromation: Catherine E. Rice at crice@cdc.gov and www.cdc.gov/autism; National Center on Birth 
Defects and Developmental Disabilities, Centers for Disease Control and Prevention, 1600 Clifton Road, MS E-86, Atlanta, Georgia, 
30333, USA. 
Conflicts of Interest: None declared.
Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position 
of the Centers for Disease Control and Prevention (CDC).
HHS Public Access
Author manuscript
Public Health Rev. Author manuscript; available in PMC 2015 July 30.
Published in final edited form as:
Public Health Rev. 2012 ; 34(2): 1–22.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
to the knowledge base about ASD prevalence in an effort to stimulate further work to understand 
the multiple reasons behind increasing ASD prevalence.
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INTRODUCTION
Autism spectrum disorders (ASDs) are neurodevelopmental conditions characterized by 
impairments in social interactions and communication and restricted, repetitive and 
stereotyped patterns of behavior that typically emerge in the first few years of life.1 ASDs 
typically refer to the three subtypes of pervasive developmental disorders of autistic 
disorder, Asperger disorder, and pervasive developmental disorder not otherwise specified.2 
In addition to the core areas of impairment in social, communication, and behavioral 
domains, people with ASDs frequently have co-occurring conditions, such as intellectual 
disability, seizures, psychiatric co-morbidities (e.g., attention deficit/hyperactivity disorder 
(ADHD), anxiety), gastrointestinal conditions, and sleep disturbance. Typically, autism is 
manifest by the time a child is three years of age and is life-long.2,3 However, there is 
variability in the pattern and severity of symptoms and in the timing of diagnosis.4
Although autism was once seen as a single disorder, incorrectly attributed to a failure of 
parenting, autism is now seen as a complex neurodevelopmental disorder that occurs with a 
range or spectrum of presentations.3 Many studies have consistently shown higher 
concordance between monozygotic as compared to dizygotic twins, suggesting there is a 
strong genetic component associated with ASDs.5,6 ASDs have been associated with 
multiple genetic variations including rare gene mutations, chromosomal deletions or 
duplications, and methylation differences. It is estimated that a specific genetic mutation can 
be identified in about ten percent to 15 percent of people with an ASD with more identified 
as technology improves.5 These mutations tend to be implicated in other conditions (e.g., 
ADHD, intellectual disability). Although multiple, complex genetic and environmental 
interactions are likely, there is very limited information on what predisposes a child to have 
an ASD, what might increase risk, and which risks lead to the development of an ASD.5,7–9
In the past autism was thought to be a rare condition, affecting about one in 2,000 
individuals.10,11 Beginning in the mid-1990s, concerns arose about increases in the numbers 
of individuals with autism identified in service systems in the United States.12,13 Population-
based studies in the US that were initiated in the 1990s14,15 found the identified prevalence 
of ASDs had increased significantly in a short time period. Multiple other studies confirmed 
this.4,12,13,16–18 Current estimates are that ASDs occur in about one percent of 
children.4,10,19–24 Prevalence estimates are important for planning policy and service needs 
and identifying potential risk factors for ASD.25 Concerns about increases in ASD 
prevalence have fueled local, state, national, and international action in terms of advocacy, 
policy-development, research, and service development. However, individuals and families 
continue to have many needs associated with ASDs across their lifespan.
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There are several potential explanations for an increase in the observed prevalence of ASDs 
including better analytic tools, better identification and screening methods, changes in 
diagnostic criteria, increased awareness among parents and clinicians, and changes in the 
availability of services. However, prevalence reports often also include the statement “a true 
increase in prevalence cannot be ruled out.”11,26 Some studies have examined how much of 
the increase is accounted for by specific risk factors, such as increasing parental age.17 
However, a full explanation must consider multiple factors that are not independent of each 
other.
This article summarizes the discussion from a workshop that was co-sponsored by CDC and 
Autism Speaks.8 The purpose of the workshop was to bring together experts in prevalence 
and surveillance of ASDs and other conditions as well as stakeholders to: summarize what is 
known about ASD prevalence; learn from efforts to document prevalence changes among 
other conditions; and improve the specificity in quantifying and qualifying the multiple 
factors that might be influencing trends in ASD prevalence. Although the focus of the 
workshop was on US-based data and trends, similar patterns are seen in other developed 
countries.19–23 Panelists discussed points for building on existing infrastructure and for 
developing new initiatives to better understand ASD trends. The information, research, and 
opinions shared during this workshop add to the knowledge base about ASD prevalence in 
an effort to stimulate further work to understand the multiple reasons behind increasing ASD 
prevalence (Table 1).8
ASD PREVALENCE
There are three main measures of occurrence of a condition: prevalence (the number of 
cases divided by the number of people in the population at a given time), incidence (the 
number of new cases among a given population in a defined time divided by the amount of 
person-time observed during the same period), and cumulative incidence (the number of 
new cases identified in an extended time period [e.g., from birth] divided by the size of the 
population without the disorder at the start of the time period). A condition where the 
diagnosis tends to be stable (e.g., low mortality rate and stable diagnosis) can result in 
prevalence and cumulative incidence measures that will be virtually identical over a defined 
time or age period.8 All measures are affected by changes in identification patterns and 
diagnostic practices. Prevalence studies can provide observations that might need further 
causal examination. For example, prevalence studies have shown that there are about four to 
five boys for every one girl with an ASD.9 However, basic studies of individuals with an 
ASD are necessary to explain the biologic mechanism that results in boys being affected 
more than girls. In addition, other types of epidemiologic studies, such as case-control 
designs may help us understand ASD risk factors.
Service-Based Data
Starting in the 1990s, the U.S. Department of Education’s Office of Special Education and 
the California Department of Developmental Services (CA DDS) documented increases in 
the need for autism services.12,13 There is an annual count of children enrolled in special 
education services as an accountability measure required by the 1990 Individuals with 
Disabilities Education Act (IDEA) based on select eligibility categories for each state.27 
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Autism was not initially a category within the child count, but states were required to report 
autism beginning in 1991. The number of children classified as having autism and receiving 
special education services has increased since the early 1990s.13 However, the total numbers 
are still fewer than would be expected given current prevalence estimates.4 A special 
education label does not always match the medical diagnosis that a child may have to 
describe developmental challenges, and enrollment counts might not have provided a true 
prevalence of ASD as the special education system never was intended to serve a public 
health surveillance role. These data are more useful in understanding variation in state-level 
special education criteria and services and examining barriers to timely identification.8
The CA DDS administrative data have been used to evaluate trends among children 
receiving services for ASD, mainly those meeting criteria for autistic disorder.12 The CA 
DDS tracks service provision for five conditions (autism, epilepsy, cerebral palsy, 
intellectual disability, and intellectual disability-related conditions) across 21 regional 
centers. Data collection is passive in that a child must be brought to a CA DDS center and a 
parent or guardian must request an evaluation to determine if they meet eligibility criteria. 
Comparing births in 1990 with those in 2001 (followed to age ten), the cumulative incidence 
of autism in the CA DDS rose 600 percent. There was substantial variability among the 
centers. About 200 percent of this increase could be explained by trends toward younger age 
at diagnosis, inclusion of more mild cases, changes in diagnostic criteria, and older ages of 
mothers.8,17,27–29 It has been estimated that about 50 percent of administrative autism 
prevalence increases in the CA DDS data could be explained by several identification 
factors, such as diagnostic changes in the use of intellectual disability (mental retardation), 
earlier age of diagnosis, social influence of people sharing information on ASDs; and 
potential risk indicators, such as closely-spaced pregnancies and increasing parental 
age.8,18,30–32 A recent study indicates that these trends are due to factors that have changed 
in a linear fashion, aggregate among birth cohorts, and disproportionately impact more mild 
forms of ASD.33 At this point, changes over time related to diagnostic criteria, methods for 
ascertainment and some risk factors appear to explain part, but not all, of the increase in 
autism cumulative incidence in the CA DDS system. However, more complex methods are 
needed to evaluate the overlapping relationships between the different and yet unstudied 
factors as they relate to ASD prevalence changes.8
Population-Based Data
Methods for determining prevalence that rely on service systems, registries, and surveys of 
people already diagnosed under-ascertain individuals with autism.4,10 Epidemiologic studies 
that systematically screen the population, which may result in identification of individuals 
who were not previously classified as having an ASD, generally result in higher and more 
complete prevalence estimates. Most epidemiologic studies of ASDs have been conducted in 
Europe, North America and areas of Asia; there is limited information on the occurrence and 
characteristics of ASDs in other areas of the world.10 Since the first epidemiologic study of 
autism prevalence in the 1960s, many studies spanning changing diagnostic criteria have 
estimated the prevalence of ASDs.
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From the 1940s until the 1980s autism primarily referred to more severely affected 
individuals with autistic disorder and was thought to be rare, affecting approximately one in 
every 2,000 (0.05%) children.10,11,26 Several studies using the current International 
Classification of Diseases (ICD-10) and the American Psychiatric Association Diagnostic 
and Statistical Manual of Mental Disorders (DSM-IV) have been conducted in industrialized 
countries identifying not only autism, but the wider spectrum indicating a best estimate of 
combined ASD prevalence at six or seven per 1,000 (0.6% or 0.7%) children.11 These 
estimates are more than ten times higher than estimates using earlier criteria. However, some 
of the most recent population-based studies have documented even higher ASD prevalence 
estimates of more than one percent,4,16,19–23 and over two percent among children in some 
areas of Asia, Europe, and North America.4,34,35
Prevalence studies that involve direct screening of a population generally report higher ASD 
prevalence estimates than those based on administrative data or service records.20,34 The 
validity of population-based screening can, however, be compromised by low response rates 
and possible false screening results. Screening can also focus more narrowly on groups at-
risk who have been identified for some type of developmental concern in order to maximize 
resources and minimize the number of children referred for diagnostic assessments. The 
CDC’s ADDM Network, a multi-site study using record review, found that 21–23 percent of 
the children identified with ASDs did not have a previous ASD classification documented in 
their records.4,16 The most recent ADDM Network estimates indicated that, on average, one 
in 88 children (range from 1 in 47 to 1 in 210) were identified with an ASD and had 
increased 78 percent over a six-year period from 2002 to 2008.4 The overall trend in ASD 
prevalence showed consistent increases, but variation existed among sites and among 
subgroups. The increase in observed ASD prevalence at ADDM Network sites could be 
partly explained by identification factors such as better information available in records, a 
more stable population at some sites, and improved identification of specific subgroups such 
as Hispanic children and children without cognitive impairment; however, these 
identification factors did not explain the total increase in prevalence.4,16,36
Data from the ADDM Network can be used to examine some of the potential factors 
impacting ASD prevalence. Although it has been stated that the changes in diagnostic 
criteria that occurred in the DSM in 1980 (DSM III), 1987 (DSM III-R), and 1994 (DSM-IV 
and minor changes for DSM-IV-TR in 2000) have affected reported ASD prevalence, no 
known studies have quantified this effect directly.10 A preliminary analysis recoding the 
ADDM Network data based on the three diagnostic standards, indicated similar autism and 
ASD prevalence using DSM III and III-R standards, but estimates increased significantly 
using DSM-IV-TR standards. A portion of the prevalence increase over time might have 
been attributed to differences in the definitions of ASD used for identification of ASDs by 
community professionals and service systems.8
Other analyses using ADDM Network data have examined a range of factors such as 
parental age, age of autism identification, perinatal risk factors, exposures, and 
socioeconomic status (SES) among others.37–41 A relatively consistent finding in recent 
epidemiologic studies is a positive association between advanced parental age at conception 
and risk of ASD in offspring.17,42 Despite the association between ASD and parental age 
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and the increasing trend in mean parental age in recent decades, only a very small (less than 
0.5%) proportion of the recent increase in ASD prevalence can be attributed to the 
increasing age of parents at conception.8 There is some evidence that indicates that ASD is 
positively associated with higher SES. In this way, it differs from many other developmental 
disabilities, which tend to be more common in socioeconomically disadvantaged 
populations.9 Examining SES among ADDM Network data, it was found that the ASD 
prevalence increased with increasing SES in a stepwise manner, suggesting either increased 
risk with increasing SES or, perhaps more likely, identification disparities.39 ASD 
prevalence estimates likely underestimate prevalence in lower SES groups. This implies that 
we are still underestimating ASD prevalence and can expect some increases if disparity gaps 
are closed over time. Further examination of characteristics across cohorts and subgroups 
will be important in understanding potential identification and risk factors contributing to 
ASD prevalence increases.8
Lessons from Other Conditions and Analytic Methods
There are other complex conditions, such as cancer, Parkinson’s disease, asthma, and 
schizophrenia, where evaluating prevalence changes and understanding biologic and 
environmental contributions has been a challenge. They provide some examples of how 
analytic models may be used to understand condition trends.8
Changes in cancer trends can be seen from changes in: 1) diagnosis or detection (e.g., 
screening and biopsy techniques); classification (e.g., staging and grading techniques); and 
3) exposures (e.g., smoking, diet, and obesity).8,43 Examining patterns of change among a 
population might explain disease trends due to changes in factors such as the annual 
frequencies of exposures, availability of screenings, use of new diagnostic technologies, and 
changes in disease coding. It is important to have data on the occurrence of a condition 
before and after the change factor being evaluated. In the case of cancer surveillance, there 
are some well-established sources of data (Surveillance, Epidemiology and End Results 
Registry; National Program of Cancer Registries).44 It is also helpful if there is a clear 
change factor that has occurred as is seen in the similar slopes of reductions in lung cancer 
following reductions in smoking.8,45 Peaks in prostate cancer prevalence were correlated 
with the introduction of the first Prostate-specific antigen (PSA) screening and when follow-
up biopsies became more routine.45
Modeling change is an integral part of cancer surveillance.8 There are several important 
lessons learned from this modeling that can be useful when examining changes in ASD 
prevalence. The basic steps of modeling change are:
• Characterizing changes in disease trends;
• Quantifying changes in the population that might explain trends;
• Identifying a mechanism for the effect of the population trend;
• Estimating the size of the effect on the risk of disease diagnosis; and
• Modeling or simulating experience among the population.
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All of these steps are equally necessary and applicable in explaining changes in ASD 
prevalence. However, modeling techniques might be useful if the potential effects of a factor 
on prevalence are not known. The Cancer Intervention and Surveillance Modeling Network 
is working to develop techniques for modeling changes in cancer based on multiple 
factors.46 The work of this group might be helpful in understanding ASD prevalence 
changes.
Parkinson’s disease is a relatively rare disorder with associated environmental and genetic 
risk factors that does not have a definitive diagnostic test or marker.8 As with ASDs, 
population-based surveillance is challenging and there have been changes in diagnostic 
criteria over time.47 Also similar to autism, there are questions about the higher prevalence 
in males and differences by race.48 Based on diagnosed cases, researchers have identified 
increased occurrence of Parkinson’s disease among men and with increasing age, a pattern 
that has been seen in most populations world-wide.47,48 However, at this point, there are few 
sources of data to examine population trends in Parkinson’s disease. The California 
Parkinson’s Disease Registry is a pilot effort to create a population-based database with 
active ascertainment and case validation, but it is a limited effort.49 Advocacy groups 
support a national surveillance system for Parkinson’s disease, but this has yet to be 
realized. Researchers are also examining conditions with similar symptoms and/or risk 
factors to identify common biologic mechanisms. It may be useful to study prevalence 
changes in other disorders with symptoms that overlap with ASDs and among adults.8,50
Asthma is a highly prevalent chronic disease. Studies have shown persistent demographic 
differences in prevalence, as well as health care use. Asthma surveillance relies on several 
national datasets such as the National Health Interview Survey (NHIS) and the Behavioral 
Risk Factor Surveillance System (BRFSS) to determine prevalence and severity.51,52 While 
asthma prevalence has increased over time, actual asthma attack rates have been relatively 
stable. The reasons for overall prevalence increases are not known, but there are 
sociodemographic disparities in identification and service use. Changes in survey 
measurement have affected asthma estimates. There is a challenge in examining asthma in 
relation to environmental factors as data are not available to look at direct measures among 
individuals in the population over time, but different datasets could be linked to conduct 
ecologic analysis of asthma survey data based on residence and air quality, for example.8
There are many parallels between schizophrenia and ASDs in the attempts to estimate and 
understand variation in incidence. With respect to schizophrenia and related psychoses, two 
landmark World Health Organization (WHO) studies can be used to mark shifts in thinking 
about schizophrenia and understanding of occurrence.52 The International Pilot Study of 
Schizophrenia (IPSS), conducted in the 1960s, was designed to determine if schizophrenia 
was a culturally bound disorder and if it was a “real” disorder (some people hypothesized 
that schizophrenia was a social construct).53,54 The study used standardized criteria in a 
multinational study and many regions of the world were included. Researchers found 
schizophrenia in all settings. Second, the WHO “Ten Country Study” examined whether the 
incidence and course of schizophrenia varied across sociocultural settings. Based on 
misinterpretation of the results of schizophrenia studies, the prevailing summary of 
schizophrenia from 1980 to about 2005 was that there was a lifetime risk of schizophrenia of 
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one percent, and that this figure remained constant over time and place. The current view on 
schizophrenia is different. It is now clear that the occurrence varies across populations and 
population subgroups, the clearest example being the very high rates among some 
immigrants who are ethnic minorities.8,54,55 The WHO studies were not designed to 
examine change over time. Although other studies have attempted to examine change over 
time (e.g., registry studies), the results have been inconsistent and the data weak (e.g., due to 
changes in diagnostic practices and systems). As a result, with the exception of one or two 
particular locations, it is unclear whether schizophrenia incidence has changed over time.8,54
There have been different waves of ideology that have influenced the way in which the data 
on incidence of ASDs have been interpreted, and in particular, on whether they demonstrate 
a “true” increase or not (“true” means over and above an increase due to changes in 
ascertainment and help-seeking). The schizophrenia example highlights the power of 
ideology in the interpretation of such data, and the need to be cognizant of it. In terms of 
ASDs, people tend to look at data as either, “yes, there has been an increase”, or “no, there 
has not been an increase”. The actual data are insufficient to draw a firm conclusion, but it is 
important to remain open to the possibility of a true increase. Commitment to either position 
is not necessary to use data to advocate for improved services.8
Analytic Models
Changes in identified ASD prevalence have been an observed phenomenon, yet the 
challenge lies in identifying the causes for the changes. Causal models, including sufficient-
component cause models, can shed some light on the joint effects of multiple exposures.8 
However, these models are unable to consider timing in a dynamic way or connections 
between individuals. A possible solution is to use complex systems models.56,57 Complex 
systems approaches are computational approaches that use computer-based algorithms to 
model dynamic interactions between individuals within and across levels of influence (such 
as social networks and neighborhoods) using simulated populations. Complex systems 
models can incorporate multilevel determinants of population health, connections between 
individuals, and patterns of feedback between exposures and outcomes over time. An 
analytic strategy for understanding multi-faceted health issues is “agent-based modeling”, 
which can be used to predict changes among heterogeneous populations. The goal is to 
model outcomes observed by varying the variables that might contribute to an observed 
pattern, such as occurrence of health effects after a disaster. In the example of a disaster, 
there could be several different sets of variables that produce the same outcome. Complex 
systems models point to different possible explanations for observed phenomenon, a point 
that is likely relevant for understanding reasons for ASD trends. However, these analytic 
methods can be used in conjunction with empirical data to narrow down possible 
explanations and can play a central role in epidemiological analyses.8
A mathematical model has been applied to assess the impact of whether specific pre- and 
perinatal risk factors effect the recent ASD prevalence trends.58 According to the ADDM 
Network, there was a 57 percent increase in ASD prevalence from 2002 to 2006.16 The 
effect of a given risk factor on prevalence depends on the baseline prevalence of the risk 
factor (RFP), the change in RFP over time (cRFP), and the magnitude of the relative risk 
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(RR). A number of previous studies have indicated that preterm birth and low birthweight 
are risk factors for ASDs.42 Other studies have implicated multiple birth, cesarean delivery, 
breech presentation, and assisted reproductive technology (ART) as possible risk factors. 
However, none has had sufficient values for RFP, cRFP, and RR to have accounted 
substantively to the recently observed ASD increase. While at an individual level, having 
one or more perinatal risk factors might convey a moderate or strong risk for ASD, these 
factors are unlikely to explain a large proportion of the population increase in ASD 
prevalence. A risk factor might be strongly associated with ASD and might be modifiable, 
but it might not have increased sufficiently in the population during the time frame of 
interest. Therefore, this risk factor might be related to an individual’s risk for ASD but not 
related to the increase in population prevalence of ASD. The model demonstrated that for 
any factor to have made a noteworthy contribution to population changes in ASD prevalence 
during a short time period, three conditions must be met: the factor must be fairly prevalent 
in the population, must have increased substantially, and must be strongly associated with 
diagnosed ASD. The model is accurate for shorter time intervals such as a few years. As the 
time period gets longer, different analytic models might be needed.
DISCUSSION
Panel members offered a range of perspectives on whether it will ever be possible to 
understand the relative contributions of identification and risk in increasing ASD 
prevalence.8 Debates about reasons for increases in ASD prevalence often have been 
dichotomized into explanations related to factors such as better identification and others 
arguing that the increase implicates specific environmental factors.59 Although it is clear 
that some of the increase is related to identification factors, a true increase cannot be ruled 
out, and furthermore, is hard to determine. In order to evaluate ASD prevalence changes, 
researchers tend to rule out alternative explanations by examining parsimonious and easily 
observable factors that could explain a difference over time, such as changes in patterns of 
identification. A more complex challenge is to search for the many potential and unknown 
risk factors that might be contributing to increases in ASD prevalence. As more data are 
collected and analyzed and different hypotheses evaluated over time and across studies, such 
risk factors can be identified.60 Despite many efforts, a single, simple explanation has not 
been found indicating that there are likely multiple, overlapping factors contributing to 
increases in ASD prevalence.
There was a general sense that it is possible to move forward and to be more specific in 
documenting potential risk factors that could account for ASD prevalence trends. Several 
challenges can be identified, such as insurmountable measurement error, overlap and 
confounding of multiple identification and risk factors, and poorly defined subtypes with 
limited information on biological underpinnings to explain phenotypes. It is unlikely that 
prevalence trend data will explain the etiology of a complex set of conditions, such as ASDs, 
but these data can identify clues for further mechanistic studies (e.g., increased risk by sex, 
geography, and birth characteristics).60 Our understanding of the potential causal 
mechanisms for ASDs makes it clear that autism is not caused solely by genetic factors. In 
general, rapid increases in a purely inherited genetic condition are unlikely. However, 
shorter-term changes can be seen through de novo mutations or epigenetic changes.5,6 There 
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is sufficient evidence to motivate the pursuit of both complex biologic and environmental 
factors in the etiologies of ASDs.61,62 Research using other methods that directly examine 
risk factors and potential causes of autism, rather than prevalence studies, will likely be most 
fruitful in clarifying the reasons for the increases in measured prevalence. In addition, we 
need more clarity on the variable expression of autism across the lifespan, and whether there 
is any association between trends for autism and other conditions. Perhaps the greatest value 
of prevalence data is that this information can lead to a focus on services and provide 
information regarding how to improve identification and access to such services.
There was agreement that the ASD prevalence is a huge public health problem and that 
many individuals and families are affected globally. At the community level, prevalence 
data have informed stakeholders about needed improvements in identifying people with an 
ASD and helped direct research that may ultimately lead to information about etiology. 
Similarly, the resulting increase in ASD awareness and knowledge among parents, 
caregivers, and communities has increased the quality of social and behavioral descriptions 
by clinicians and service providers when a child has been referred for an evaluation. This 
has resulted in parents and professionals being more equipped to discuss concerns. 
Individuals with an ASD have also benefitted from ASD prevalence data with increased 
ASD awareness related to positive community connections and increased information has 
allowed them to help themselves and others understand their experience. Prevalence 
estimates also have informed policy efforts to create an infrastructure to support children 
with an ASD (e.g., child care, intervention, education, transition services); understand and 
address lifespan issues (e.g, early identification, housing training, employment, health and 
wellness); drive public policy and programs (e.g., insurance coverage and health care 
legislation); and support the need for service deployment, systems planning, and additional 
research funding.
WHAT CAN BE DONE?
Throughout the workshop, ideas for building on existing infrastructure and for developing 
new initiatives to better understand ASD trends were discussed.8 In particular, efforts are 
needed to improve the specificity in quantifying and qualifying the multiple factors that 
might be influencing trends in ASD prevalence. These suggestions for improving our 
understanding of ASD trends are included below:
1. Collaboration: Collaboration among professionals and stakeholders is important, 
and the following points may assist collaborative efforts among those interested in 
understanding ASDs and supporting the ASD community through science:
• Continue efforts to develop and enhance communication among families, 
individuals affected, researchers, service providers, advocates, and 
government entities about ASD prevalence, research, and service needs.
• Seek public–private partnerships to support data collection, analyses, and 
usage.
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• Seek input from and collaboration with those in other fields, such as cancer 
epidemiology, to identify and utilize methodologies for evaluating changes 
in the prevalence of complex conditions.
• Collaborate with other data systems to improve access to population-level 
environmental data.
2. Analytic Activities: Improve utilization of existing data to understand ASD 
prevalence trends:
• Provide funding opportunities to encourage analyses and dissemination of 
findings from existing datasets.
• Link existing datasets identifying children with ASDs to other health, 
service, and research databases.
• Conduct analyses that will help explain variations in ASD prevalence across 
subgroups (e.g., race and ethnicity, sex, diagnostic subtype, and geographic 
groups) and if variation persists over time.
• Use complex modeling and multifactorial analyses to better understand 
variation in ASD prevalence such as by possible etiologic subgroups (e.g., 
specific genetic conditions and family history), geography, and sex, and by 
potentially harmful exposures among cohorts.
• Conduct simulation studies to predict the anticipated course of ASD 
prevalence.
3. Data Enhancements to Inform Practice: Data on the prevalence and characteristics 
of people with an ASD should be used to better inform service and support efforts:
• In addition to prevalence estimates, provide more in-depth information on 
population characteristics of people with an ASD (such as functional level 
and impact of functional limitations, subtype, developmental characteristics, 
and associated conditions) to improve program planning and support needs.
• Examine data to better understand lags and disparities in ASD identification 
to, in turn, inform screening, identification, and program planning.
• Conduct analyses to provide better estimates of current and future needs of 
adults with an ASD.
4. Additional Studies: Beyond enhancements to existing data systems and uses, new 
types of data collection and studies are needed, including:
• Expand ASD prevalence efforts to include very young children and adults.
• Examine prevalence over time among older children by following up with 
those identified in previous studies.
• Conduct additional validation studies at various ADDM Network sites and 
use the results to enhance estimates of ASD prevalence.
Rice et al. Page 11
Public Health Rev. Author manuscript; available in PMC 2015 July 30.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
• Conduct further studies to better understand who is identified and who is not 
identified in national parent report surveys and in service-based data such as 
special education child counts.
• Develop ways of better capturing the heterogeneity of ASD phenotypes 
including the complexity of core and associated features that may present in 
different combinations for people with an ASD.
• Improve tools for culturally sensitive screening and case confirmation 
among large populations.
• Identify ways to measure and monitor the traits associated with ASDs 
among the general population to reflect various degrees (dimensional) rather 
than categorical (having an ASD or not having an ASD) case vs. not case) 
levels. This includes characterizing how these traits overlap with other 
conditions and typical development.
• Conduct prospective cohort, cross-sectional, and longitudinal studies 
following cohorts over time. This could include examining trends in 
characteristics of the population, such as ASDs among specific subgroups 
(based on, for example, race and ethnicity, immigrant status, and SES), age 
of identification, diagnoses, comorbidities, services use, and family 
characteristics.
• Monitor trends in ASD prevalence prospectively to rule out identification 
factors by consistently conducting developmental and ASD screening at a 
given age with diagnostic follow-up and documentation of each step and 
outcome.
• Conduct prospective studies that examine biology, phenotype, identification 
patterns, and service needs and use of people with an ASD.
• Expand international prevalence work to examine variability in occurrence 
that may shed light on identification and risk factors for ASDs.
• Examine trends in other behaviorally defined conditions (e.g., ADHD, 
depression, and anxiety).
SUMMARY
The identified prevalence of ASD has increased significantly in a short time period across 
multiple studies. ASDs are conditions estimated to occur among about one percent or more 
of children from multiple studies. Prevalence studies provide descriptive data on the number 
of people with a condition in a defined population. These studies are not sufficient to 
identify what causes ASDs. However, prevalence studies can be used as tools to examine 
variation in occurrence of ASDs across place, groups, time, and exposures, which may 
provide clues about groups that are at increased risk for ASDs. Other study designs would 
be necessary to fully investigate the reasons behind observed variation in ASD prevalence. 
At this point, it is clear that identification factors have had an impact on the identified 
prevalence, but no single factor explains the changes identified in ASD prevalence over 
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time, and much needs to be done to understand the relative contribution of the multiple 
factors involved. Additionally, there are likely several forms of ASDs with multiple causes 
that are currently poorly understood. It was noted that sufficient evidence exists that biologic 
and environmental factors, alone and in combination need to be considered as causes of 
ASDs. By better understanding what causes ASDs, we may be able to understand the 
increases in measured prevalence.
Prevalence estimates have fueled action by advocacy groups and policy makers. However, 
individuals, families, and communities continue to have to address unmet needs across the 
lifespan of people with ASDs. ASDs are conditions that affect more individuals than 
previously thought and concerted efforts are needed to address the many associated needs of 
individuals, families, and communities in the context of a public health approach that 
includes improving preconception care for all, early medical and developmental screening 
and assessment, and needed support services across the lifespan.
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Table 1
Categories of Factors that May Influence ASD Prevalence Trends
1. Intrinsic Identification Internal methodology or measurement factors involved in documenting ASD prevalence trends (e.g., differences 
in study methods may lead to different individuals being counted or not counted as having an ASD such as using 
a registry of children identified with an ASD or active screening).
2. Extrinsic Identification External classification and awareness factors involved in identifying people with ASDs in the population (e.g., 
changes in diagnostic criteria or access to services based on an ASD label may influence who is identified for 
ASD prevalence studies).
3. Risk Possible etiologic or true change in ASD symptoms among the population in relation to single or combined 
genetic, biologic, or environmental factors, or a combination thereof (e.g., specific biologic vulnerabilities or 
exposures in the environment that increase the risk of developing an ASD).
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